Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690340 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL3075660 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2690339 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2690338 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL19915056 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL29102381 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL26143938 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL220833 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL622600 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL26363782 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790753-B2 | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-09-07 | — | — | US | disclosed |
| US-20060223861-A1 | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223861-A1 | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | SNCA, CHRNA5, GABRE | CHRM2 27/4885CHRM1 18/4885CHRM3 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.